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Abstract 
To evaluate the influence of prognostic factors related to patient selection on survival data, 
survival outcomes were retrospectively analyzed using our institutional consecutive series of 67 
newly diagnosed glioblastoma multiforme (GBM) patients who had received either conventional 
fractionated photon radiotherapy (CRT) or high-dose particle radiotherapy (HDT). 
In CRT protocol, a total dose of 60.0-61.2 Gy was administered. In HDT protocol, an averaged 
dose of approximately 30 GyEq at a single session and additional fractionated photon irradiation at a 
total dose of 30 Gy was administered in boron neutron capture therapy, and a total dose of 96.6GyEq 
was administered in proton therapy. Most of the patients had received chemotherapy with nimustine 
hydrochloride (ACNU) alone or with ACNU, procarbazine, and vincristine. The median overall and 
progression-free survival time for all patients was 17.7 months (95% CI, 14.6 – 20.9) and 7.8 months 
(95% CI, 5.7 – 9.9), respectively. The one- and two-year survival rate was 67.2% and 33.7%, 
respectively. The median overall survival time (OS) was 24.4 months (95% CI, 18.2 – 30.5) for 
patients treated with HDT, compared with 14.2 months (95% CI, 10.0 – 18.3) for those with CRT. 
The Cox proportional hazards model revealed radiation modality (HDT vs. CRT) and EORTC-RPA 
class to be the significant prognostic factors. Age, sex, preoperative performance status, treatment 
with or without advanced neuro-imaging, extent of surgery, and regimen of chemotherapy were not 
statistically significant. The median OS was 18.5 months (95% CI, 9.9 – 27.1) in patients 65 years 
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and older, compared with 16.8 months (95% CI, 13.6 – 20.1) in those 64 years and younger 
(p=0.871).  
The relatively positive survival data of selected patients who underwent HDT are unlikely to 
reflect patient selection alone. Randomized trials with strictly controlled inclusion criteria for the 
comparable selection of patients will still be required to demonstrate conclusively that prolonged 
survival can be attributed to these high-dose particle radiotherapies. 
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Introduction 
Glioblastoma multiforme (GBM) is a highly infiltrative primary malignant brain tumour in adults.  
The prognosis of GBM is generally extremely poor, and there has been little improvement in survival 
rates over the past three decades [1, 2].  Several randomized trials have demonstrated the survival 
benefits of conventional fractionated photon radiotherapy at a total dose of 45 to 60 Gy; the median 
overall survival time (OS) in these trials was 5.8 to 15.5 months [3–7]. Currently, conventional 
fractionated photon radiotherapy of approximately 60 Gy with concomitant and adjuvant use of 
temozolomide has been recognized as the standard postoperative treatment for newly diagnosed 
GBM [8, 9]. However, the five-year survival rate with this standard therapy is less than 10 % [9], 
suggesting that alternative therapeutic strategies are desperately needed. 
Most dose escalation studies of radiotherapy have been designed as case series of a small number 
of selected patients who underwent additional stereotactic radiosurgery, fractionated proton beam 
radiation, or intensity-modulated radiotherapy or another type of conformal radiotherapy [10-12]. 
Studies showing the better outcomes (median OS range: 9.5 - 25 months) suggested that a radiation 
dose of at least 90 Gy of hyperfractionated radiotherapy should be used for irradiation in order to 
accomplish local tumour control. However, there has been no randomized controlled trial (RCT) to 
provide evidence in support of these favorable data, nor has there been any trial warranting a 
follow-up study using any form of high-dose radiotherapy [10, 13]. Thus, controversy remains 
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regarding not only the efficacy of high-dose radiotherapy but also regarding the influence of strict 
patient selection on outcomes achieved with this type of treatment. High-dose irradiation of a 
small-volume target could minimize central recurrence and any radiation dose-dependent adverse 
events in such trials. However, recurrences often occur in the target volume receiving a relatively 
low-dose treatment. The five-year survival rate with conventional-dose radiotherapy alone is reported 
around 1% [9], which suggested a limitation of conventional-dose radiotherapy in most patients. 
We recently reported two different types of high-dose particle radiotherapy using boron neutron 
capture therapy (BNCT) and proton therapy (PT). These radiotherapies for newly-diagnosed GBM 
were administered based on different selection criteria, and both showed an acceptable OS (i.e., 25.7 
months in the BNCT group, and 21.6 months in PT group), with acceptable adverse events [14, 15]. 
Previously, several different factors (e.g., age, preoperative performance status [PS], tumour location, 
extent of surgery, and conventional radiotherapy) have been shown to be prognostic of survival in 
patients with GBM [16-20]. Here we aimed to evaluate the influence of such patient selection-related 
factors on survival. Survival outcomes and prognostic factors were retrospectively analyzed using 
our institutional consecutive series of newly diagnosed GBM patients who had received either 
conventional fractionated photon radiotherapy (CRT) or high-dose particle radiotherapy (HDT). In 
the present paper, we report the combined updated results of all patients treated by both forms of 
particle therapy. 
6 
 
 
Materials and Methods  
We investigated 67 consecutive patients with newly diagnosed supratentorial GBM (grade IV) who 
were treated at Tsukuba University Hospital from January 1998 to August 2007. The patients were 
histopathologically diagnosed according to the classification system of the World Health 
Organization. Some of the survival data for patients who received PT or BNCT have been reported in 
earlier publications using different follow-up periods and survival analysis determinations [14, 15]. 
Maximal safe resection was intended to remove all gadolinium (Gd)-enhanced masses observed by 
magnetic resonance (MR) imaging, i.e., the surrounding non-eloquent brain tissue was targeted for 
removal, with the aim of preserving neurological function in unresected areas of eloquent brain tissue. 
To this end, 5-aminolevulinic-acid-induced fluorescence guidance, neuronavigation, as well as 
intraoperative monitoring were incorporated into the treatment. The navigation-guided fence-post 
procedure was carried out as previously reported [21] in order to treat non-eloquent portions of 
tumours. In cases involving tumours located close to areas of eloquent tissue, we inserted silicon 
tubes along the boundary between the eloquent and non-eloquent tissue, as indicated by MR images. 
The phrase “advanced neuro-imaging” was used to refer to all surgical interventions involving 
fluorescence guidance and/or neuronavigation. 
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The postoperative radiation schedule for patients with GBM treated at our facilities consisted of 3 
protocols. As the standard radiotherapy, daily CRT (1.8 - 2.0 Gy) was administered five times per 
week, amounting to a total overall dose of 60.0 – 61.2 Gy. For selected patients, HDT was used, 
consisting of either BNCT or PT. In the BNCT protocol, the gross tumor volume (GTV) and clinical 
target volume (CTV)-1 were defined as the residual gadolinium-enhancing volume. CTV-2 and 
CTV-3 were defined as GTV plus a margin of 2 cm and 3 cm, respectively. An averaged dose of 
approximately 30 GyEq at a single session, and additional fractionated photon irradiation at a total 
dose of 30 Gy was administered to GTV. The detailed protocol of BNCT has been described 
elsewhere [14]. BNCT was administered to patients with a supratentorial unilateral tumour located at 
no deeper than 7 cm from the brain surface, and who had a Karnofsky performance status (KPS) of 
50 or more. In the PT protocol, CTV-1 was defined same as BNCT. On the other hand, CTV-2 was 
defined as GTV plus a margin of 1 cm and CTV-3 was defined as the surrounding edema. 
Furthermore, in the PT protocol, the planning target volume (PTV) was adopted that was defined as 
the CTV plus a margin of 5 mm for setup error. Conventional photon radiotherapy (50.4 Gy in 28 
fractions) was delivered to PTV-3 in the morning. In the first half of the protocol, additional 
concomitant boost proton radiotherapy (23.1 GyE in 14 fractions) was delivered to PTV-2 more than 
6 hours after photon radiotherapy. Then, in the latter half, proton radiotherapy (23.1 GyE in 14 
fractions) was delivered to PTV-1. As a result, the total dose for PTV-1 was 96.6 GyE in 56 fractions, 
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73.5 GyE in 42 fractions for PTV-2, and 50.4 Gy in 28 fractions for PTV-3 [15]. The following 
criteria were used to select patients for PT: the presence of a supratentorial tumour lacking 
involvement of the brain stem or thalamus, a maximum postoperative tumour diameter of less than 4 
cm, and a KPS of 60 or more. BNCT was administered to 15 patients and PT to 17 patients. The PAV 
combination regimen of procarbazine, nimustine hydrochloride (ACNU), and vincristine was 
administered as the standard concomitant chemotherapy combined with CRT. For patients at high 
risk for adverse events with PAV therapy (i.e., elderly patients, patients in poor neurological or 
general condition), ACNU alone was typically used as the concomitant chemotherapy. ACNU was 
also used in combination with HDT. 
 
Statistical analysis 
Statistical analyses were performed using SPSS software (version 11.0.1J; SPSS, Inc.). Overall 
survival and progression-free survival were used to investigate the prognostic impact of the variables 
analyzed. OS was defined as the time lapse from surgery until death or the final follow-up. 
Progression-free survival time was defined as the time lapse from surgery until a detection of 
progression or the final follow-up. Survival probabilities were calculated using the Kaplan-Meier 
method, and differences among patient groups were evaluated using the log-rank test. The Cox 
proportional hazards model was used to test the following prognostic factors in univariate and 
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multivariate analyses: age (<65 years vs. ≥65 years), sex (female vs. male), preoperative PS (0 -2 vs. 
3-4), European Organization for Research and Treatment of Cancer (EORTC) recursive partitioning 
analysis (RPA) class (III-IV vs. V) [21], advanced neuro-imaging (with vs. without), extent of 
surgery (complete resection vs. others), chemotherapy (ACNU vs. other), and radiation modality 
(HDT vs. CRT).  
Factors with a probability value of less than 0.05 on univariate analysis were selected for testing in 
the multivariate analysis. Results are expressed with relative risk and a 95% confidence interval (CI). 
 
Results 
The characteristics of the 67 patients are summarized in Table 1. Included in the analysis were 34 
men and 33 women aged 31 to 84 years (median, 59.0 years). Surgical resection resulted in complete 
resection of the tumour in 13 (19%), partial resection in 47 (70%), and biopsy in 7 (10%) patients. 
Forty-seven (70%) patients received chemotherapy with ACNU or other agents. Thirty-two (48%) 
received HDT and thirty-five (52%) received CRT; consequently, all 67 patients received either one 
or the other type of radiotherapy. There were 6 (9%) patients with a WHO PS of 0, 30 (45%) with a 
PS of 1, 12 (18%) with a PS of 2, 10 (15%) with a PS of 3, and 9 (13%) with a PS of 4. Whereas 9 
patients (13%) were categorized as having the best GBM prognosis (class III), 21 (31%) were in 
class IV, and 37 (55%) were in class V, according to the EORTC-RPA classification system. 
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Nine patients were alive at the time of analysis with a mean follow-up time of 21.4 (range 1.0– 
71.2) months. The median OS for all patients was 17.7 months (95% CI, 14.6 – 20.9). The one- and 
two-year survival rates were 67.2% and 33.7%, respectively. The median progression-free survival 
time in this series was 7.8 months (95% CI, 5.7 – 9.9). The one- and two-year progression-free 
survival rates were 32.6 and 18.4%, respectively. 
The univariate and multivariate analyses of prognostic factors in this study are shown in Tables 2 
and 3, respectively. The multivariate analysis revealed radiation modality and EORTC RPA class as 
significant prognostic factors. The median OS was 24.4 months (95% CI, 18.2 – 30.5) for patients 
treated with HDT, compared with 14.2 months (95% CI, 10.0 – 18.3) for those treated with CRT (Fig. 
1). Other previously reported prognostic factors such as age, sex, preoperative PS, treatment with or 
without advanced neuro-imaging, extent of surgery, and regimen of chemotherapy were not 
statistically significant according to the multivariate analysis. The median OS was 18.5 months (95% 
CI, 9.9 – 27.1) in patients 65 years and older, compared with 16.8 months (95% CI, 13.6 – 20.1) in 
those 64 years and younger (p=0.871). 
Patients who were treated with HDT had a significantly better preoperative PS than patients treated 
with CRT (p=0.025). Similarly, patients who were treated with HDT were more likely to have 
undergone complete resection than patients treated with CRT (28.1% compared to 11.4%; p=0.078) 
and were more likely to be categorized in the better prognostic group (III-IV compared to V; 
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p=0.059); however, neither of these differences were statistically significant. Other clinical 
characteristics, i.e. age, sex, advanced neuro-imaging, and regimen of chemotherapy were not 
found to differ between patients who underwent HDT and those treated with CRT (Table 4). 
 
Discussion 
The median OS for all patients was 17.7 months; a longer median OS of 24.4 months was seen in 
the HDT group, compared to 14.2 months in the CRT group. Receiving either HDT or CRT was also 
factored out as a significant independent prognostic factor. The survival data for the CRT patients in 
this study were comparable to those of previous reports of patients treated with the standard therapies. 
Patient selection (e.g., age, PS, etc.) for the HDT group appeared not to be a major factor influencing 
survival time, nor did it negatively influence the survival time of the CRT patients. 
It is generally accepted that the concomitant and adjuvant use of temozolomide with conventional 
fractionated photon radiotherapy can be effective for treating post-operative GBM with minimal 
additional toxicity, and a significant survival advantage has been demonstrated for this approach 
compared to the administration of radiotherapy alone. The median OS in this RCT reported was 14.6 
months with temozolomide-plus-radiotherapy, and 12.1 months with radiotherapy alone [8]. The 
median OS of CRT patients observed in this study was comparable to that of patients in the 
temozolomide treatment arm, whereas the median OS of all patients in this study was longer than that 
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of the patients in the temozolomide treatment arm. The patient characteristic data from the report by 
Stupp and colleagues showed that patients in the temozolomide treatment arm tended to be younger 
and better PS (0-1) populations, and belong to less-high risk (EORTC-RPA class V) populations 
(Table 5). These findings suggest that the favorable survival data of all patients and those of patients 
who underwent HDT in this study were unlikely to reflect patient selection alone. However, better 
extent of surgery (complete resection; 39% compared to 19%), more-moderate risk (EORTC-RPA 
class IV; 53% compared to 31%) populations, aggressive salvage treatment, and other indeterminate 
factors e.g. surgical technique, administration of standard care etc. may have positively influenced 
the survival data. Additionally, small sample size, inconsistent and non-controlled patient 
characteristics, may have affected the results and thus pose limitations on the findings of the present 
study. 
Here, the median OS of GBM patients increased from 15.2 months (95% CI, 8.1 – 22.3) between 
1982 and 1997 to 17.7 months (95% CI, 14.6 – 20.9) between 1998 and 2007, although this trend 
was not statistically significant (p=0.086). The 2-year relative survival rate also increased from 
23.6% between 1982 and 1997 to 33.7% between 1998 and 2007. Advancements in surgical 
techniques such as fluorescence guidance (since 1999) and in neuronavigation (since 2005), as well 
as improvements in chemotherapeutic agents, have been implemented at our institute; however, no 
significant differences in the extent of surgery or chemotherapy regimen were observed between 
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these two periods of time (i.e., pre-, post-1998). There remains no reliable evidence supporting these 
surgical approach and chemotherapy regimen as regards OS. Therefore, the improvements in OS may 
not have been related to surgical approach, but rather to changes made to the BNCT protocol since 
1998 and those made to the PT protocol since 2001, when rotating gantries and regular daily 
fractionation became possible. 
In BNCT series, acute toxicities such as mild erythema (commonly observed), transient orbital 
swelling in 1 patient (6.7 %) were observed. On the other hand, No late toxicity was observed in the 
follow-up periods. In PT series, acute toxicities such as radiation dermatitis (commonly observed), 
rash in 1 patient (5.9 %), and headache in 5 patients (29.4 %) were observed. As for late toxicity, 
radiation necrosis in 1 patient (5.9 %) and leukoencephalopathy in 1 patient (5.9 %) were observed 
[14, 15]. Although these data indicate that toxicity in our HDT protocol seems to be acceptable at the 
analysis, incidence of late toxicities of survivors such as radiation necrosis and leukoencephalopathy 
remains to be monitored and clarified in longer follow-up time. 
Patient age has been reported as a strong prognostic factor in the treatment of GBM. In the RPA of 
EORTC, being 50 years old or older is a significant prognostic factor in the categorization of disease. 
However, in the present study, no correlation was found between age and prognosis. Recently, 
significant improvement in the survival of elderly patients with GBM has been observed with the 
introduction of aggressive treatments [23-25]. In the present series, almost no statistically significant 
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difference was observed in age-related survival probability. The mean age of PT and BNCT patients 
was 57 and 60 years, respectively. Aggressive treatment of elderly patients with GBM at our institute 
appears to have minimized the difference in age-related survival probability.  
Patients who were treated with HDT had a better preoperative PS and were more likely to have 
undergone complete resection than patients treated with CRT. It was not possible to separate the 
effects of HDT from the selection bias toward patients with a better prognosis, because the inclusion 
criteria of our HDT modalities, which are based on the characteristics of GBM patients, involve the 
restriction of PS and the limitations of tumour size and location, both of which are correlated with the 
difficulty of resection. However, even in patients categorized in the worst prognostic group 
(EORTC-RPA class V), OS was significantly prolonged for those who had received HDT compared 
to those treated with CRT (p=0.007). Similarly, among patients who underwent partial resection and 
biopsy, the OS was also significantly prolonged for those who received HDT versus those treated 
with CRT (p=0.005). These results indicate that the survival benefits of HDT appear unlikely to 
reflect patient selection alone. 
 
Conclusions 
It is generally accepted that both the size and location of a tumour, as well as patient performance 
status, should be considered in evaluations of the safety and efficacy of high-dose particle 
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radiotherapies. In this study, patients selected to receive HDT showed longer survival times 
compared than those treated with CRT. Although HDT, compared to CRT, was factored out as a 
significant favorable prognostic factor, other major prognostic factors did not appear to be 
confounding. The results of this study suggest that the relatively positive survival data of patients 
selected to undergo HDT are unlikely to reflect patient selection alone. Randomized trials with 
strictly controlled inclusion criteria for the comparable selection of patients are required to 
demonstrate conclusively that prolonged survival is a result of these high-dose radiotherapies.  
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Figure legends 
 
Figure 1 
Kaplan-Meier estimates of overall survival according to radiation modality. The hazard ratio for 
death among patients treated with high-dose radiotherapy, as compared to that among patients treated 
with conventional fractionated photon radiotherapy, was 0.44 (95% CI, 0.26– 0.76; p<0.01). 
 
Table 1 
Characteristics of 68 patients with glioblastoma multiforme 
* Advanced neuro-imaging indicates 5-aminolevulinic-acid-induced fluorescence guidance and 
neuronavigation   
**Radiation Therapy Oncology Group (RTOG)-RPA class VI patients were included in 
EORTC-RPA class V 
 
Table 2 
Univariate analysis of prognostic factors for the survival of patients with glioblastoma multiforme 
 
Table 3 
Multivariate analysis of prognostic factors for the survival of patients with glioblastoma multiforme  
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Table 4 
Clinical characteristics of patients treated with HDT compared to CRT  
 
Table 5 
Comparison of patient characteristics in the TMZ-plus-CRT arm of EORTC 26981/22981-NCIC 
patients and all patients in this study 
* Authors calculated 
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Table. 1 
 
Characteristics No. of Patients（%） 
Age  
 
median  59.0 years 
range  31 to 84 years 
Sex  
 
male  34(51%) 
female  33(49%) 
Side  
 
left  33(49%) 
right  27(40%) 
midline or bilateral  7(10%) 
Location  
 
frontal lobe  32(48%) 
temporal lobe  19(28%) 
parietal lobe  17(25%) 
occipital lobe  1(1%) 
other  6(9%) 
Advanced neuro-imaging*  
 
yes  31(46%) 
no  36(54%) 
Extent of surgery  
 
complete  13 (19%) 
partial  47 (70%) 
biopsy  7 (10%) 
Chemotherapy  
 
nimustine hydrochloride  45(67%) 
other  2(3%) 
none  20(30%) 
Radiotherapy  
 
high dose  32(48%) 
conventional dose  35(52%) 
WHO performance status  
 
0 6 (9%) 
1 30 (45%) 
2 12 (18%) 
3 10 (15%) 
4 9 (13%) 
EORTC-RPA class**  
 
III 9(13%) 
IV 21(31%) 
V 37(55%) 
 
Table. 2 
 
Variable Hazard ratio (95% CI) p Value 
Age (<65 years vs. ≥65 years)  0.954 (0.539-1.687)  0.871  
Sex (female vs. male)  0.600 (0.351-1.023)  0.061  
WHO performance status (0-2 vs. 3-4)  0.525 (0.295-0.936)  0.029  
EORTC-RPA class (III-IV vs. V)  0.502 (0.289-0.872)  0.014  
Advanced neuro-imaging (with vs. without)  0.731 (0.430-1.244)  0.248  
Extent of resection (complete vs. others)  0.735 (0.379-1.424)  0.361  
Chemotherapy (ACNU vs. others)  0.632 (0.365-1.091)  0.100  
Radiotherapy (high dose vs. conventional dose)  0.443 (0.258-0.762)  0.003  
 
Table. 3 
 
Variable Hazard ratio (95% CI) p Value 
WHO performance status (0-2 vs. 3-4)  0.634 (0.352-1.142)  0.129  
EORTC-RPA class (III-IV vs. V)  0.544 (0.310-0.954)  0.034  
Radiotherapy (high dose vs. conventional dose)  0.495 (0.284-0.862)  0.013  
 
Table. 4 
 
Characteristics No. of Patients（%） p Value 
 
high dose conventional dose 
 
age 
   
  <65 24 22 
0.210 
  ≥65 8 13 
sex 
   
 male 14 20 
0.198 
  female 18 15 
Advanced 
neuro-imaging    
 yes 14 17 
0.441 
 no 18 18 
extent of surgery  
   
  complete resection  9 4 
0.078 
  others 23 31 
chemotherapy 
   
  ACNU 21 24 
0.501 
  others 11 11 
WHO performance 
status     
  0-2  27 21 
0.025 
  3-4  5 14 
EORTC-RPA class 
   
  III-IV  18 12 
0.059 
  V  14 23 
 
Table. 5 
 
Characteristics CRT plus TMZ This study 
Number of patients  287 67 
Age  
  
median  56 years 59 years 
range  19 to 70 years 31 to 84 years 
Sex  
  
male  185(64%) 34(51%) 
female  102(36%) 33(49%) 
Extent of surgery  
  
complete  113 (39%) 13 (19%) 
partial  126 (44%) 47 (70%) 
biopsy  48 (17%) 7 (10%) 
WHO performance status  
  
0 113 (39%) 6 (9%) 
1 136 (47%) 30 (45%) 
2 38 (13%) 12 (18%) 
3 0 (0%) 10 (15%) 
4 0 (0%) 9 (13%) 
EORTC-RPA class  
  
III 42(15%) 9(13%) 
IV 152(53%) 21(31%) 
V 93(32%) 37(55%) 
   
No. of progression 244 (85%) 59 (88%) 
Salvage surgery 66* (27%) 20 (34%) 
Salvage chemotherapy 142* (58%) 54 (92%) 
 
